Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722044 · ClinicalTrials.gov registry record · Phase 3
Usability of an AI for M923 in Subjects With Moderate to Severe RA
A Phase 3 study of Rheumatoid Arthritis, sponsored by Momenta Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
- 7
- Study locations
NCT02722044 is a Phase 3 study of Rheumatoid Arthritis that has completed, run by Momenta Pharmaceuticals. The registered enrollment target is 33 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT02722044, a Phase 3 study of Rheumatoid Arthritis, has completed, sponsored by Momenta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)
Conditions Studied
Interventions
- DEVICE Autoinjector
- BIOLOGICAL M923
Study Locations (7)
Texas
- Austin Regional Clinic, PA - Austin
- Accurate Clinical Management - Houston
- Accurate Clinical Research, Inc. - Houston
Michigan
- Henry Ford Health System - Detroit
North Carolina
- Medication Management, LLC - Greensboro
Oklahoma
- Lynn Health Science Institute - Oklahoma City
Pennsylvania
- Altoona Center for Clinical Research, PC - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-02-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02722044
The ClinicalTrials.gov registry entry for NCT02722044 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is Momenta Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Autoinjector is the first listed.
NCT02722044 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Texas, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02722044 about?
NCT02722044 is a clinical study titled "Usability of an AI for M923 in Subjects With Moderate to Severe RA". The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)
What is the current status of trial NCT02722044?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2016-04. Estimated completion is 2017-02-21.
What conditions does trial NCT02722044 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT02722044?
The interventions under investigation include: Autoinjector (DEVICE), M923 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02722044?
This trial is sponsored by Momenta Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02722044 being conducted?
This trial has 7 study locations across Michigan, North Carolina, Oklahoma, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.